Search

Search Results
Results 291 - 300 of 302 for Short bowel syndrome
  • Loette (New Formulation)
    Drug - 16 Nov 2020
    Consumer Medicine Information (CMI) about Loette (New Formulation) (Levonorgestrel and Ethinylestradiol Tablets) intended for persons living in Australia.
  • Lecteva
    Drug - 15 Oct 2020
    Consumer Medicine Information (CMI) about Lecteva (levodopa/carbidopa/entacapone) intended for persons living in Australia.
  • Abstral sublingual tablets
    Drug - 5 Aug 2020
    Consumer Medicine Information (CMI) about Abstral sublingual tablets intended for persons living in Australia.
  • Loette
    Drug - 13 Dec 2019
    Consumer Medicine Information (CMI) about Loette (Levonorgestrel and Ethinylestradiol Tablets) intended for persons living in Australia.
  • Nordette
    Drug - 12 Dec 2019
    Consumer Medicine Information (CMI) about Nordette (Levonorgestrel and Ethinylestradiol Tablets) intended for persons living in Australia.
  • Monofeme
    Drug - 12 Dec 2019
    Consumer Medicine Information (CMI) about Monofeme (Levonorgestrel and Ethinylestradiol Tablets) intended for persons living in Australia.
  • Micardis® (Telmisartan) Consumer Medicine Information
    Drug - 20 Jun 2019
     
  • Coveram
    Drug - 2 May 2024
    Consumer Medicine Information (CMI) about Coveram intended for persons living in Australia.
  • Trifeme
    Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about Trifeme intended for persons living in Australia.
  • Minulet
    Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about Minulet intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback